South Korean proteomics company Bertis expands to the US

Protein molecule

Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence.

The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an analysis platform to integrate multi-omics data.

Proteomics, the study of proteins in the human body, has emerged as a promising field in medicine, particularly for its potential to identify subtypes of cancers and match patients with the most appropriate treatment strategy.

In South Korea, Bertis created MASTOCHECK, the world’s first proteomics-based breast cancer blood test solution. The test received marketing approval as an in vitro diagnostic medical device from the Ministry of Food and Drug Safety in January 2019.

In September, Bertis’ research team presented protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC) with 95% accuracy. The results of this study were published in the Journal of Proteome Research by the American Chemical Society.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free